3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Melanoma
50
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
11
Neoplasm Metastasis
10
Carcinoma, Renal Cell
7
Skin Neoplasms
5
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Lung Neoplasms
4
Glioblastoma
4
Diabetes Mellitus, Insulin-Dependent, 12
4
Carcinoma, Hepatocellular
4
Brain Neoplasms
4
Advanced Cancer
4
Uveal Melanoma
3
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Recurrence
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Breast Neoplasms
3
Waldenstrom Macroglobulinemia
2
Sarcoma
2
Myeloproliferative Disorders
2
Lymphoma, Mantle-Cell
2
Interventions
pembrolizumab
3
Carboplatin
3
Nivolumab
2
Injections
2
Docetaxel
2
Cisplatin
2
BMS-753493
2
zimberelimab
1
urelumab
1
tislelizumab
1
tesetaxel
1
spartalizumab
1
olaparib
1
liposomal doxorubicin
1
linifanib
1
lenvatinib
1
ixabepilone
1
durvalumab
1
avelumab
1
avdoralimab
1
adavosertib
1
TAS-119
1
Rifampin
1
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
1
Maximum Tolerated Dose
1
Linoleic Acids, Conjugated
1
Lapatinib
1
Itraconazole
1
Irinotecan
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Advanced Solid Tumors
×
Ipilimumab
×
Clear all
NCT03461952
2024-02-22
NIMBLe
Canadian Cancer Trials Group
Phase 2
Terminated
4 enrolled
4 charts